Research and Markets: Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/p4hkwz/clozaril) has announced the addition of the "Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide.

While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Clozapine belongs to the dibenzazepine class of psychotropics and it is marketed under the brand names Clozaril and Leponex by Novartis, and FazaClo (an ODT formulation) by Jazz Pharmaceuticals. The drug is unique in its receptor-binding profile: thanks to its receptor selectivity, Clozaril should be considered in patients who fail to respond to two consecutive antipsychotics (one of which should be atypical) and in patients who display persistent suicidality.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Clozaril including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Clozaril for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Clozaril (clozapine)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/p4hkwz/clozaril

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System